Skip to main content
Glama

Hubspot

by io.github.pipeworx-io

Entity Profile

entity_profile
Read-onlyIdempotent

"Tell me about X" / "research Acme" / "brief me on Tesla" / "what does Apple do" / "company profile for Microsoft" / "give me the rundown on NVDA" / "everything you know about $TICKER" — full cross-source profile of a US public company in ONE parallel call. ALWAYS PREFER over chaining single-pack SEC/XBRL/news lookups when the user asks for a holistic view. Fans out across SEC EDGAR, XBRL, USPTO patents, federal contracts (USAspending), FDA-licensed biologics (Purple Book), H-1B hiring (DOL LCA), news and GLEIF, and returns: cik + company_name (+ resolved_from/resolved_to when value was a name); recent_filings (up to 5 with pipeworx://edgar/company/{cik}/filings/{accession} URIs); fundamentals (LATEST 10-K Revenues + NetIncomeLoss + Cash, sorted period_end DESC); patents (USPTO PatentsView API sunset May 2025 — soft-fails until reactivated); federal_contracts (USAspending awards where the company is the recipient); fda_products (FDA-licensed biologics — vaccines, cell/gene therapies — from the Purple Book; a company with only small-molecule/generic drugs will show none here, that is expected, not a failure); hiring (H-1B sponsorship volume + salary range from DOL LCA filings); recent news mentions via GDELT→GNews fallback; LEI via GLEIF. sources_used / sources_failed say which of these actually returned data for THIS company — an empty section is a real "no data", not a bug. Pass a ticker ("AAPL"), zero-padded CIK ("0000320193"), OR a company name ("Moderna") — names now resolve via SEC EDGAR's company-name match; a private company (no CIK/ticker) returns resolved:false with an explicit notes line, not a bare failure. type accepts "company" or "ticker" interchangeably — both take the same value shapes above.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYes"company" or "ticker" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon.
valueYesTicker (e.g., "AAPL"), zero-padded CIK (e.g., "0000320193"), or company name (e.g., "Moderna") — names resolve via SEC EDGAR company-name match.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed3 schema fields changed
    • changedInput schema / properties / type / description
      Previous value: -"Entity type. Only \"company\" supported today; person/place coming soon."New value: +"\"company\" or \"ticker\" — both are accepted and behave identically; `value` can be a ticker, CIK, or company name either way. person/place coming soon."
    • changedInput schema / properties / type / enum
      Previous value: -[
-  "company"
-]New value: +[
+  "company",
+  "ticker"
+]
    • changedInput schema / properties / value / description
      Previous value: -"Ticker (e.g., \"AAPL\") or zero-padded CIK (e.g., \"0000320193\"). Names not supported — use resolve_entity first if you only have a name."New value: +"Ticker (e.g., \"AAPL\"), zero-padded CIK (e.g., \"0000320193\"), or company name (e.g., \"Moderna\") — names resolve via SEC EDGAR company-name match."
  2. Added

TDQS

A4.6/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already declare read-only, idempotent, non-destructive behavior, and the description adds substantial context beyond that: source fan-out list, USPTO soft-fail behavior, expected empty fda_products for small-molecule-only companies, sources_used/sources_failed semantics, and resolved:false handling. No contradiction with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

Long but dense, and front-loaded with usage examples followed by the core definition. Every segment about return sections and failure modes adds needed context, especially since there is no output schema, though the opening example list is slightly overlong.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Despite having no output schema, the description enumerates all major return sections (CIK, filings, fundamentals, patents, contracts, FDA products, hiring, news, LEI) and explains source success/failure semantics. It gives enough information for an agent to call the tool correctly without requiring additional lookups.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Schema description coverage is 100% and already documents ticker/CIK/name, the type enum, and interchangeability. The description mostly restates this with examples; it adds useful behavioral context around private-company resolution but not much new parameter meaning beyond the schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a specific resource (a US public company) and action (build a full cross-source profile), with many concrete query examples. It differentiates the tool from chaining single-pack SEC/XBRL/news lookups and positions it as a holistic one-call research tool.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It explicitly says to ALWAYS PREFER this tool over chaining single-pack lookups when the user asks for a holistic view, and provides trigger-phrase examples and accepted input forms. It also sets scope expectations: private companies return resolved:false with notes rather than a bare failure.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Hubspot toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.5/5.0
Disambiguation2/5

Several tools are near-duplicates or overlapping entry points: ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded, deep_research, discover_tools, and suggest_questions all serve overlapping query/discovery purposes. The polymarket tools and HubSpot tools are more distinct, but the set as a whole has fuzzy boundaries between many members.

Naming Consistency2/5

Naming is inconsistent across the set: HubSpot tools use an hs_ prefix, Pipeworx tools mostly use bare verbs (ask_pipeworx, recall, forget), and other tools mix styles (ai_visibility_check, generate_llms_txt, polymarket_edges). The hs_* subset is consistent, but overall there is no single predictable pattern.

Tool Count2/5

38 tools is too many for the apparent scope, especially since the server is named 'Hubspot' but only 6 of the tools are HubSpot-specific. A large portion of the catalog covers unrelated Pipeworx data access, prediction markets, memory, and npm scanning, making the set feel bloated and unfocused.

Completeness2/5

The HubSpot portion of the tool set is read-only: it can get, list, and search companies/contacts/deals, but has no create, update, or delete operations, leaving obvious lifecycle gaps. If the intended domain is actually Pipeworx/data research, the HubSpot tools seem like an unrelated afterthought, so the surface is incomplete for either interpretation.

Resources